383 related articles for article (PubMed ID: 16614256)
1. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Pfaller MA; Diekema DJ; Sheehan DJ
Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
[TBL] [Abstract][Full Text] [Related]
2. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Pfaller MA; Diekema DJ; Rex JH; Espinel-Ingroff A; Johnson EM; Andes D; Chaturvedi V; Ghannoum MA; Odds FC; Rinaldi MG; Sheehan DJ; Troke P; Walsh TJ; Warnock DW
J Clin Microbiol; 2006 Mar; 44(3):819-26. PubMed ID: 16517860
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Rex JH; Pfaller MA; Galgiani JN; Bartlett MS; Espinel-Ingroff A; Ghannoum MA; Lancaster M; Odds FC; Rinaldi MG; Walsh TJ; Barry AL
Clin Infect Dis; 1997 Feb; 24(2):235-47. PubMed ID: 9114154
[TBL] [Abstract][Full Text] [Related]
5. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
6. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
7. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Cuesta I; Bielza C; Cuenca-Estrella M; Larrañaga P; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2010 Apr; 54(4):1541-6. PubMed ID: 20124002
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
Enwuru CA; Ogunledun A; Idika N; Enwuru NV; Ogbonna F; Aniedobe M; Adeiga A
Afr Health Sci; 2008 Sep; 8(3):142-8. PubMed ID: 19357740
[TBL] [Abstract][Full Text] [Related]
9. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
10. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.
Ostrosky-Zeichner L; Rex JH; Pfaller MA; Diekema DJ; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):4175-7. PubMed ID: 18809944
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
[TBL] [Abstract][Full Text] [Related]
13. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2008 Feb; 46(2):551-9. PubMed ID: 18094129
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
15. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
[TBL] [Abstract][Full Text] [Related]
17. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
18. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin disk diffusion breakpoints and quality control.
Brown SD; Traczewski MM
J Clin Microbiol; 2008 Jun; 46(6):1927-9. PubMed ID: 18400918
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.
Spreghini E; Maida CM; Tomassetti S; Orlando F; Giannini D; Milici ME; Scalise G; Barchiesi F
Antimicrob Agents Chemother; 2008 Jun; 52(6):1929-33. PubMed ID: 18391037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
